-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
HPV is a common virus.
if not vaccinated, most sexually active people will have a lifetime chance of contracting HPV.
most infected people have removed the virus, it is still possible to develop HPV-related cancers and pre-cancer or genital warts.
many people infected with HPV may not have any symptoms, which means they can unknowingly spread the virus to others.
HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 cause about 90% of cervical cancer and 75-85% of cervical cancer, respectively.
9 types of HPV can also cause at least 75% of HPV-related vulvity, vaginal and cancers, as well as pre-cancer.
more than 90% of genital warts are caused by type 6 and type 11 HPV.
Merck recently announced that the 9-price human papillomavirus (HPV) vaccine GARDASIL®9 has acquired a new adaptation that can be used in men between the ages of 9 and 45 to prevent anal cancer, anal abnormalities and precancerog lesions, as well as warts.
This new adaptation is proportion to the gardaSIL®9 original adaptation, which is suitable for girls and women between the ages of 9 and 45 and is used to prevent cervical, vulverty, vaginal and anal cancers, as well as abnormalities and precancerog lesions caused by nine types of cancer.
women's health specialist, explains: "This new clinical tool further contributes to cancer prevention in men."
.